Therapeutic Benefit in Allergic Dermatitis Derived from the Inhibitory Effect of Byakkokaninjinto on the Migration of Plasmacytoid Dendritic Cells

Figure 4

The effects of byakkokaninjinto components on BMpDC migration. The number of migrated BMpDCs with the treatment of each component (0.10 mg/ml) is indicated by the line graph; (a) data are expressed as the mean ± SE (, vs. the vehicle; n = 3). The effects of each component of byakkokaninjinto at doses of 0.02 mg/ml, 0.05 mg/ml, and 0.10 mg/ml on the velocity and directionality of BMpDC migration were measured by an EZ-TAXIScan chemotaxis assay. The bar chart shows the change rates of BMpDC migration velocity (b) and directionality (c) induced by treatment at each dose versus treatment with the vehicle. Data are expressed as the mean ± SE (, vs. the vehicle; n = 3).

(a)

(b)

(c)